Health & Fitness
Mon, May 10, 2010Sun, May 9, 2010Sat, May 8, 2010Fri, May 7, 2010Thu, May 6, 2010Mon, January 11, 2010Sat, January 9, 2010Fri, January 8, 2010Thu, January 7, 2010Wed, January 6, 2010Tue, January 5, 2010Mon, January 4, 2010Thu, December 31, 2009Wed, December 30, 2009Tue, December 29, 2009Mon, December 28, 2009Thu, December 24, 2009Wed, December 23, 2009Tue, December 22, 2009Mon, December 21, 2009Fri, December 18, 2009Anika Therapeutics to Discuss Acquisition of Fidia Advanced Biopolymers During Special Conference Call Today
Published in Health and Fitness on Monday, January 4th 2010 at 10:30 GMT by Market Wire
BEDFORD, Mass.--([ BUSINESS WIRE ])--[ Anika Therapeutics, Inc. ] (Nasdaq: ANIK) announced that it plans to conduct a special conference call, today, Monday, January 4, 2010 at 10 a.m. (Eastern time) to provide an overview of the acquisition of Fidia Advanced Biopolymers and other business and financial matters affecting the Company, some of which may contain information that has not been previously disclosed. To listen to the conference call, dial 800-299-7089 (International callers dial 617-801-9714) and use the passcode 31471402. Please call approximately 10 minutes before the starting time and reference Anika Therapeutics. In addition, the conference call will be available to interested parties through a live audio webcast in the [ "Investor Relations" ] section of Anika's website, [ www.anikatherapeutics.com ]. An accompanying slideshow presentation also can be accessed via the Anika Therapeutics website. The call will be archived and accessible on the same website shortly after the conclusion of the call.
The webcast also is being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at [ www.earnings.com ], Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents ([ www.streetevents.com ]), a password-protected event management site.
About Anika Therapeutics, Inc.
Headquartered in Bedford, Mass., [ Anika Therapeutics, Inc ]. develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on [ hyaluronic acid (HA) ], a naturally occurring, biocompatible polymer found throughout the body. Anika's products include [ ORTHOVISC ]®, a treatment for osteoarthritis of the knee available internationally and marketed in the U.S. by DePuy Mitek; [ HYVISC® ], a treatment for equine osteoarthritis marketed in the U.S. by Boehringer Ingelheim Vetmedica, Inc.; the ELEVESS, ELEVESS Light, and HYDRELLE family of aesthetic dermatology products for facial wrinkles, scar remediation and lip augmentation; [ AMVISC®, AMVISC® Plus, STAARVISC™-II and Shellgel™ ] injectable viscoelastic HA products for ophthalmic surgery; [ INCERT® ], an HA-based anti-adhesive for surgical applications; [ ORTHOVISC®mini ] a treatment for osteoarthritis targeting small joints and available in Europe; [ MONOVISC™ ] a single-injection osteoarthritis product based on Anika's proprietary cross-linking technology and available in Europe, Turkey and Canada; and next generation products for joint health and aesthetic dermatology based on the Company's proprietary, chemically modified HA.
